

receipt #6

PATENTS

In re application of: Moser et al. Serial No: 09/862,798)		
)	Docket Number:	A180 1010
)		
Filed:	May 22, 2001)		
For:	COMPOSITIONS AND METHO FOR PROMOTING OR INHIBIT ANGIOGENESIS	•		

REQUEST FOR CORRECTION TO THE FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Sir:

This is a request for correction of the Filing Receipt in connection with the above-identified patent application. Please delete the "LARGE ENTITY" designation. A copy of the Filing Receipt with the corrections noted thereon in red ink is enclosed. Please send a corrected Filing Receipt to the below-listed attorney.

The above-identified application was inadvertently filed with the wrong fee. Applicants are obligated to assign their rights to a small entity. Applicant requests that the difference between the large entity fee payment and the small entity fee payment be credited to Deposit Account No. 09-0528. This error is being corrected within a reasonable time after it was discovered.

The Commissioner is hereby authorized to charge any additional fee(s) and/or credit any overpayments to Deposit Account No. 09-0528. This document is submitted in duplicate.

Respectfully submitted,

David S. Bradin

Attorney for Applicant

Reg. No. 37,783


Womble Carlyle Sandridge & Rice

P.O. Box 7037

Atlanta, GA 30357-0037 Telephone: (919) 484-2382

Facsimile: (919) 484-2380

RTP 50394v1



TED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231

www.uspto.gov

LING DATE

GRP ART UNIT

FIL FEE REC'D

ATTY.DOCKET.NO

DRAWINGS

TOT CLAIMS 52

IND CLAIMS

09/862.798

05/22/2001

1646

963

A180 1010

11

CONFIRMATION NO. 1167

WOMBLE CARLYLE SANDRIDGE & RICE, PLLC

2.O. Box 7037

Allanta, GA 30357-0037

OC000000006403370

Date Mailed: 08/09/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Tammy L. Moser, Durham, NC; Salvatore V. Pizzo, Bahama, NC; Mary S. Stack, Chicago, IL;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/314,159 05/19/1999 WHICH CLAIMS BENEFIT OF 60/086,155 05/19/1998 AND CLAIMS BENEFIT OF 60/124,070 03/12/1999

Foreign Applications

If Required, Foreign Filing License Granted 08/08/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Lavge SMALL ** SMALL ENTITY **

Title

Compositions and methods for promoting or inhibiting angiogenesis

Preliminary Class

Data entry by : NGUYEN, NGAN

Team : OIPE

Date: 08/09/2001

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231